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System Partnerships between Medical Device Companies and 
Health Care Providers 
Elisabeth Ludwig 
The American health care system has some of the worst quality outcomes and high-
est costs internationally. In order to address these issues, the Medicare Access and 
CHIP Reauthorization Act (MACRA) was passed in 2015 by Congress. MACRA 
is a new value- and quality-based payment model which rewards providers for high 
quality care and penalizes providers with low quality outcomes. Under the law, two 
health care payment models, the Merit-based Incentive Payment System and Alter-
native Payment Models, put patients as the focus to promote patient-centered health 
care. Providers have difficulties adapting to these new models, but through system 
partnerships they can be supported. System partnerships are relationships between 
medical device companies and providers which are more than common customer-
vendor relationships. In fact, system partnerships aim to develop complex treatment 
solutions together. This paper reviews whether system partnerships can effectively 
lower costs and improve the quality of health care systems. In addition, the ad-
vantages of the system partnerships, such as digitalization, are compared to the risks 
they pose to patients and providers, such as information asymmetries. At present, 
analysis of these factors shows that the advantages outweigh the risks. Therefore, 
the use of system partnerships as a means to lower costs and improve quality is 
recommended.  
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1 Introduction 
The American health care market is one of the largest in the world and acts as a role 
model for other countries. Every legislative change is observed and discussed because 
its size can illustrate problems and advantages more explicitly than other, smaller mar-
kets can.  
This paper will discuss whether system partnerships between medical device companies 
and providers save costs and improve the quality of care. To accomplish this, MACRA 
is briefly explained (section 2) and its impact on providers is detailed in section 3. Sec-
tion 4 presents how the providers deal with the new regulation and what problems might 
occur. A description follows of possible solutions that could be implemented to support 
the providers with adapting to this legislation, emphasizing system partnerships as a 
possible solution (section 5). Thereafter, the advantages and opportunities a system part-
nership provides, the risks presented by these partnerships under MACRA, as well as 
cost savings and quality improvement will be discussed (section 6). At the end, a con-
clusion will be drawn which considers the presented results of the previous sections. 
2 MACRA 
The American health care system has some of the world’s highest expenses for health 
care, but also some of the worst quality outcomes when compared to different countries 
(Squires, Anderson,2015, w.s.). In order to tackle this imbalance, the government intro-
duced the Medicare Access and CHIP Reauthorization Act (MACRA) in 2015 (Medi-
care Access and CHIP Reauthorization Act, 2015, w.s.). With MACRA in place, CMS 
strives to achieve better, more patient-focused care. The system is intended to be under-
standable and flexible for each participating physician. It rewards high-quality patient 
care through two options: The Merit-based Incentive Payment System (MIPS) or the 
Alternative Payment Model (APM). Both payment systems and their rewards are de-
scribed in the following section.  
2.1 Merit-based Incentive Payment System 
The Merit-based Incentive Payment System (MIPS) will affect almost every physician 
because any physician which earns at least $10,000 from Medicare payments is involved 
in this payment reform (Shinkman, 2016, w.s.). The new system combines and unites 
multiple quality and value programs which were formerly separate into one. 
MIPS mainly lays focus on three aspects: quality, resource use, and use of certified elec-
tronic health record (EHR) technology. Performance will be measured and reported in 
four performance categories. The first, quality, will compose 50% of the measurement 
taken in the first years of MACRA and is therefore the most important part of the meas-
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uring. The second one is resource use, which is the only category that is directly meas-
ured by CMS and will compose 10%. The third one clinical practice improvement ac-
tivities has rather lower importance at the beginning of the reporting period because it 
was not included in former laws and needs to be introduced to the physicians. The last 
one is the meaningful use of EHR certified technology (Yaraghi, 2016, w.s.). 
The four performance categories will be pooled together into a MIPS composite perfor-
mance score (CPS). This CPS will be used to decide whether a physician receives an 
upward, downward, or even no payment adjustment to either reward or penalize the 
provider. Quality, resource use, and meaningful use of certified EHR technology were 
present in former laws and have now been modified, extended, and transformed into 
one. The report for quality performance must include at least six measures, one trans-
sectoral measure, and, if possible, one outcome measure (Medicare Access and CHIP 
Reauthorization Act, 2015, w.s.). In lieu of an outcome measure, there is the option to 
add a high priority measure such as patient safety. The required clinical practice im-
provement activity, the only new regulation, addresses population management and care 
coordination. CMS will annually establish a new performance list with additional de-
tailed information about changes to MIPS and the metrics of the CPS after the collected 
data is submitted. 
2.2  Alternative Payment Model 
The second payment system reform option is the Alternative Payment Model (APM). 
To be part of the program, a physician must meet a higher Medicaid revenue or patient 
threshold than under MIPS. It will only affect 5% of health care systems and is used to 
establish some kind of better and newer accountable care organizations (ACO). Most 
ACOs are APMs, but not all APMs are ACOs because there are a variety of possible 
models for APMs. The requirements for an advanced APM are the following: having a 
quality measure component, using EHR certified technology, and either bearing more 
than a nominal financial risk or being part of a Medical Home Model (an expansion 
under the authority of the Medicare and Medicaid Innovation Center) (Medicare Access 
and CHIP Reauthorization Act, 2015, w.s.). Those who participate in the most advanced 
APMs will be upgraded to Qualifying APM Participants (QP). QPs are physicians and 
practitioners who have a certain percentage of their patients or payments through an 
eligible APM. Those who qualify to be a QP gain a 5% bonus payment from 2019 – 
2024 and after 2026 receive higher fee schedule updates than under MIPS as detailed in 
figure 9.1 (Hussey, Liu, White, 2017, pp. 697-705). 
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Figure 1: MACRA fee schedule timeline comparing Fee Schedule Updates, MIPS, and APMs 
 
Source: own illustration 
MIPS will include all eligible clinicians except those who participate in an APM. 
Whereas APMs are designed for larger practices, MIPS is designed for smaller and solo 
practices. APMs have a greater risk, however, and this is rewarded with higher bonuses 
than in MIPS.   
Both models are applicable to payment for Medicare and Medicaid patients. Those two 
forms of public insurance originate from the federal government and cover about 34% 
of the American population (Kaiser Family Foundation, 2015, w.s.). These models often 
align with CMS regulations closely as they consider them important guidelines for 
health care payment system success. 
3 Providers´ challenges with MACRA 
MACRA mainly affects providers, meaning they must now adjust to the new payment 
models, which often implies a difficult process. 
According to MACRA, there are four main domains to which the providers must adjust. 
The first domain is quality, where providers have to measure the quality of their perfor-
mance in six different ways. Within this process, providers can choose their own means 
of measurement (Pullen, 2017, pp. 591-592). This is a difficulty because it might invite 
providers to exploit the system (Yaraghi, 2016, w.s.). Consequently, providers can easily 
manipulate the measurements and present themselves as better than they actually are. In 
general, quality measurement is complicated because the patient as well as the physician 
should ideally describe results of care episodes. Quality is often a personal perception 
and therefore it is challenging to design a conclusive survey which depicts the situation 
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in an objective way. In addition, health care providers do not have the ability to access 
all data being submitted to CMS (Deloitte Report, 2017, p. 5).  
The second domain is resource use, with its performance being calculated by using ad-
ministrative data. Therefore, physicians and providers do not have to submit any addi-
tional data (Medicare Access and CHIP Reauthorization Act, 2015, w.s.). However, ob-
taining this data is very complex because it cannot be extracted from one source 
(Deloitte Report, 2017, p. 6). Usually, CMS also does not communicate the results to 
providers more than once a year, which can lead to invalid responses to the system, 
which means that changes cannot be made without the data. However, this issue has 
already been detected and addressed by simplifying the reporting requirements for the 
first year of MACRA.  
The third domain involves clinical practice improvement activities. These are difficult 
to identify because there is no data infrastructure yet to measure performance in this 
domain (Deloitte Report, 2017, p. 11).  
The meaningful use of EHR certified technology is the last domain. EHR certified tech-
nology is expensive, hence it is easier for larger providers to equip themselves with than 
it is for solo practitioners. More than 600 EHR manufacturers sell the technology to 
providers across the US health system (Deloitte Report, 2017, p. 5). Even though 60% 
of the provider market is supplied through 5 EHR companies, the large variety of sys-
tems and vendors make it complicated to synthesize and compare data by setting or 
provider. Consequently, there are many different and incompatible EHR systems in the 
American health care market.  
Many physicians reported that the MACRA performance documentation may distract 
them from actual patient care due to the excessive bureaucratic burden (Shinkman, 2016, 
w.s. and Shyrock, 2016, p. 2). CMS reacted to these objections by loosening the re-
strictions. Currently, providers can select between three options in order to avoid a neg-
ative payment adjustment. All these options introduce the participant to the new value-
based payment system to encourage conformity with the requirements of the system 
over time (Medicare Access and CHIP Reauthorization Act, 2015, w.s.). 
It is expected that MACRA will drive physicians to join larger organizations and net-
works to be part of APMs and their payment advantages, thus increasing participation 
in value based-payment agreements (Survey of US Health Care Executives, 2016, p. 7). 
However, the law might disrupt the relationships between health care systems, physi-
cians, and life science companies like medical device companies and pharmaceuticals, 
creating barriers. Nevertheless, these parties need to work together to overcome obsta-
cles in providing quality care. Therefore, alliances between health care systems and life 
science companies will be significant in order to evaluate which products work best on 
which type of patient to achieve better treatment outcomes and improve cost efficiency 
(Lohmann, Rippmann, 2014, pp. 127-131).  
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4 System partnerships 
Providers need to optimize and digitalize medical processes in order to secure quality 
and efficiency in the health care sector, an endeavor that is complicated and expensive. 
Often providers cannot afford these expensive innovations, so they simply try to save 
costs by dismissing staff. This in turn leads to poor quality care and eventually leads to 
negative payment adjustments (Lohmann/Rippmann, 2014, p. 122). Add something here 
about how system partnerships can avoid that scenario and how you will discuss the 
positive and negative aspects of these partnerships in this section. 
4.1 Positive aspects of a system partnership 
To be successful under MACRA, providers need to completely change the way they 
have been working (Deloitte Report, 2017, p. 1). One way to become successful is to 
establish a system partnership with a medical device company. Such a partnership means 
that the two entities have more than a common customer-vendor relationship; this im-
plies a full partnership where they develop and establish treatment solutions together 
(Siemens Healthineers, 2015, w.s.). A variety of partnerships exist, creating tailored so-
lutions for every possible cooperation between medical device companies and providers. 
On one hand, providers often need to invest in their digital infrastructure or innovate in 
general (Lohmann, Rippmann, 2014, pp. 122-131), but they often do not have the finan-
cial reserves to do so. On the other hand, Medical device companies are able to support 
these changes financially through multiple payment models which ease the payment for 
providers. Additionally, they can provide them with medical devices to clear the way 
for further innovation processes, given that they are in a system partnership. As a result, 
the provider can participate in the progress of medical technology without worrying 
about financial resources. 
The provider can further benefit from cooperation with a medical device company by 
using the company as a positive role model for modernization of health care (Lohmann, 
Rippmann, 2014, p. 126). Currently, medical device companies are global players who 
have to align to the market. Providers are protected by law and thus never had to adjust 
to the global market in the same way. However, now that the market is changing through 
MACRA, providers are forced to compete on a higher level. Medical device companies 
can encourage providers to take steps in the direction of digitalization. They can assist 
providers in terms of restructuring and reorganizing while also relieving the company 
financially and motivating the staff through quick wins in digitalization.  
Medical device companies can also teach staff how to optimally operate devices and 
technology, generating an efficiency gain (Lohmann, Rippmann, 2014, p. 128). Also, 
the companies have the expertise to analyze weak points in a process and subsequently 
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help to optimize those. Together, the two partners have the opportunity to use the devel-
opment work of the medical device company to create change more swiftly than previ-
ously possible.  
If the providers and medical device company cooperate closely together, they are also 
able to establish clinical pathways together. Clinical pathways are the unitary way, 
agreed upon by all concerned parties, a provider treats patients with steady, proficient 
quality (Lohmann, Rippmann, 2014, pp. 122-131). It is determined to be the most effi-
cient way to treat a patient and is complex to develop. When the provider and all relevant 
employees along with the medical device company agree to devise a clinical pathway, 
it will be especially efficient.  
Sometimes medical device companies collaborate to facilitate product improvements 
(Siemens Healthineers, 2015, w.s.). There are various products that can be innovated 
and upgraded, such as Magnetic Resonance Imaging (MRI) and Computerized Axial 
Tomography (CAT) scans. A partnership with a provider allows scrutiny of workflows 
and improvement of the device accordingly. For example, Siemens Healthineers and 
Northwell Health have been collaborating since December 2016 as a research partner-
ship in order to improve the outcomes of Northwell’s Imaging Clinical Effectiveness 
and Outcomes Research Program (Business Wire, 2016, w.s.). According to their first 
published paper, 'Value of Advanced Imaging in Improving Health Outcomes and 
Healthcare Spending in Acute Stroke', they already discovered that during a stroke the 
best choice for an imaging exam, whether to use an CT or MRI, depends on the personal 
characteristics of the patient. With this finding, Siemens Healthineers and Northwell 
Health hope to illuminate new pathways to treat patients more effectively and influence 
health policy rulings to improve population health.  
4.2 Negative aspects of a system partnership 
There are some factors, however, which providers and medical device companies should 
bear in mind when considering a partnership. Both parties need to be completely honest 
about their intentions when establishing a working relationship (Lohmann, Rippmann, 
2014, p. 130). If there are any discrepancies it is highly likely that the cooperation will 
not work. Constant risk management is a necessity to detect possible inconsistencies 
early enough to rectify the situation. Also, credibility is an important matter. If the pro-
vider does not believe the intentions of the medical device company are genuine there 
is no basis to build on and thus it is likely that the partnership will not come about 
(KMU-, Krankenhausstudie 2000, 2000, pp. 94-100). 
Furthermore, not every medical device company is able to establish a system partner-
ship. There are special features needed for a partnership to occur. The structure of the 
company has to be more like a service company than a simple vendor (Lohmann, Ripp-
mann, 2014, p. 127). These service qualities are essential to be successful in such a 
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partnership due to the thorough preparations which are needed to determine if the two 
partners fit well together before founding the partnership. 
5 Discussion 
In the following part, the focus lies on the central question: to what extent can a system 
partnership between a provider and a medical device company can save costs and sim-
ultaneously improve the quality? 
First of all, it is apparent that there is a need for change in the health care market 
(Squires, Anderson, 2015, w.s.). MACRA expresses these needs and tries to take a step 
toward a better functioning health care market. To accomplish this, providers have to 
leave old pattern of fee-for-service logic. MACRA is a law propels providers into value-
based payment reform and therefore makes changes inevitable.  
The providers also have to digitalize. This might be expensive at first, however, as soon 
as the provider gets used to it expenses can be saved. In a partnership, the medical device 
company may help the provider to acclimate to new devices and new technology, allow-
ing providers to benefit from the profound knowledge of the device company. The med-
ical device company is then able to develop the products and sell them to the provider. 
Naturally, the company has more detailed insight into the product than the provider. 
This insight can be communicated to the provider and customized to the specific re-
quirements the provider requests. Both can benefit from economies of scale and the 
medical device company can profit from economies of scope as well. A medical device 
company usually has more than one provider with whom it collaborates. After the new 
technology is incorporated, the provider is highly likely to receive higher revenues under 
MACRA, under the condition that the medical device company provides EHR certified 
technology and the provider reports the performance categories correctly.  
Research partnerships, especially, can play an integral part in quality improvement. The 
medical device company and the provider work together to scrutinize topics which can 
contribute to excellent patient care provision. For example, imaging techniques can be 
enhanced and the evaluation of images can be simplified for physicians. Consequently, 
the rate of misinterpreted images might decrease and thus might lower the rate of incor-
rect diagnoses. There may then be more satisfied and correctly treated patients, which 
is an indicator for high quality as well as value in the health care market. If there are less 
wrong diagnoses, there are fewer follow-up treatments, which also would lead to de-
creasing costs. As a further result, quality would be improved as well by decreasing 
unnecessary care. Additionally, medical device companies can use collected data to im-
prove all their devices and develop new devices. Older technologies will be replaced 
through this process in the near future. Consequently, providers will be provided with 
better technologies and the medical device companies can market more products.  
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When the medical device company tackles the burden of inefficient processes by opti-
mizing them, both partners can focus on their core activities. It is particularly important 
for providers to focus on their core capacity to revise actual treatments. This is required 
to have a competitive edge against other providers (Lohmann, Rippmann, 2014, p. 129). 
If a provider has established clinical pathways together with a medical device company, 
both better concentrate on the maximal performance. The medical device company sup-
ports the provider to implement the provider’s ideas, expectations, and suggestions. To-
gether, they are able to achieve state-of-the-art medicine and improve the quality of 
treatments dramatically. Additionally, both can improve their images. Hence, the medi-
cal device company will gain more customers and the provider more patients. Both ben-
efit from an excellent status and thus can save costs through economies of scale, leading 
to a positive effect on their revenue as well. 
Physicians in a system partnership focus more on medical outcomes because their part-
ner releases them of incidental economic, technical, and organizational issues to a great 
extent. Also, nursing staff is disburdened from supplementary documentation obliga-
tions and other administrative tasks so they can concentrate more on patients. Through 
such a system partnership, resources are efficiently used and will be reimbursed to a 
greater extent by MACRA. 
Another notable point is that medical device companies can support providers by build-
ing up a good data infrastructure. It simplifies data collection and data transfer to fulfill 
MACRA reporting requirements, which is likely to result in higher payments. Also, to-
gether they can evaluate the data better to review the number of mistakes made by each 
physician and create competition by rewarding physicians who made the least mistakes. 
This will also increase the quality of care and is an effective incentive to save costs from 
unnecessary follow-up treatments. 
Additionally, if the provider receives all the required devices from the same medical 
device vendor, there is only one maintenance contract to negotiate. Consequently, the 
maintenance complexity is reduced and more standardization is achieved. Every device 
is similarly programmed and this leads to simplified usage for every physician. Now 
only one introduction from the medical device company is needed for the staff to explain 
how to use a device properly and in the best, fastest way. In general, standardization is 
essential for faster and more efficient working practice. Also, the reduced complexity of 
maintenance contracts saves time and resources. Fewer staff members are required to 
check the contracts with each individual device company and therefore costs are re-
duced.  
However, only a functioning system partnership offers the advantages listed above. If a 
system partnership does not achieve this there are severe disadvantages which must al-
ways be kept in mind. 
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The many barriers to effective cooperation are seen as a negative aspect. Partners must 
compromise, a process which distracts the provider from focusing completely on provid-
ing health care. Also, medical device companies do not wish to cooperate with every 
provider. They mainly focus on larger health providers to get better outcomes. Smaller 
health providers do not have the scope the medical device companies want to reach with 
those partnerships. Additionally, the larger providers supervise a higher number of pa-
tients each day. If they can save costs through system partnerships, it will affect the 
health care economy more than if the medical device companies would only cooperate 
with smaller providers. Furthermore, larger providers have a higher negotiation level 
than smaller ones. They can achieve better conditions for the system partnership due to 
their size. More medical devices and technologies are needed in larger organizations and 
it is a greater challenge for the medical device company. Therefore, more costs can be 
avoided by the providers due to volume discount. However, the medical device company 
has a secure customer through the system partnership, who relies on its products and to 
whom it can sell more as an economic benefit despite the volume discount. 
A major aspect of the partnership is the dependency between the provider and medical 
device company. Once a partnership is established, the provider is dependent on the 
medical device company. The provider needs to believe in the good intentions of the 
medical device company (KMU-, Krankenhausstudie 2000, 2000, pp. 94-100) and try 
to keep the possible dependencies as minimal as possible. This can be accomplished 
through customer-vendor relationships with other medical device companies. Along the 
same lines, the medical device company is prompted to reveal all its intentions so it is 
evident that the company does not want to exploit the provider. If such abuse took place, 
it would first lead to significantly higher costs for the provider and the system partner-
ship would finally end in a collapse. 
Nevertheless, the advantages of correctly aligned system partnerships between two par-
ties outweigh the risks of a partnership not properly functioning. Even though it is ex-
pensive at first, innovation is necessary. Through this process, quality can be signifi-
cantly increased and costs decreased due to modification of health care systems in the 
US through various system partnerships.  
6  Conclusion 
The health care market is a fast-changing market. MACRA takes a step in a new direc-
tion which has significant influence on how providers function. The need for change had 
been obvious before the law passed through Congress. MACRA now helps the health 
care market adjust faster to the new circumstances it faces. Providers are now required 
to change within the next couple of years. They have four years to align with the new 
payment models and become quality- and value-based providers. System partnerships 
between providers and medical device companies are a model which will support those 
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changes and help both parties perform at their best. Though smaller providers will not 
benefit as much from system partnerships now, they are expected be attractive for med-
ical device companies as well in a few years. 
System partnerships facilitate the repositioning providers to focus on their core compe-
tencies in order to improve medical outcomes. The medical device companies take bur-
dens from providers and support them with technological knowledge and innovations. 
Clinical effectiveness and economics can significantly be improved through these part-
nerships as well, creating another benefit for both participants.  
Already established partnerships demonstrate the huge advantages both sides have ex-
perienced from their system partnership. These also show the possible variety of part-
nerships. Every system partnership differs and the medical device company has to adjust 
to each provider. This process leads to creative and innovative solutions which exem-
plify how system partnerships benefit providers, medical device companies, and the 
health system as a whole, especially in the future. Therefore, this concept of system 
partnerships has to be further developed in order to minimize the risks and focus on the 
advantages.  
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